Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Retained Earnings: 2020-2024

Historic Retained Earnings for Foghorn Therapeutics (FHTX) over the last 5 years, with Dec 2024 value amounting to -$558.2 million.

  • Foghorn Therapeutics' Retained Earnings fell 13.38% to -$610.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$610.8 million, marking a year-over-year decrease of 13.38%. This contributed to the annual value of -$558.2 million for FY2024, which is 18.37% down from last year.
  • Per Foghorn Therapeutics' latest filing, its Retained Earnings stood at -$558.2 million for FY2024, which was down 18.37% from -$471.6 million recorded in FY2023.
  • In the past 5 years, Foghorn Therapeutics' Retained Earnings ranged from a high of -$162.9 million in FY2020 and a low of -$558.2 million during FY2024.
  • Over the past 3 years, Foghorn Therapeutics' median Retained Earnings value was -$471.6 million (recorded in 2023), while the average stood at -$467.6 million.
  • Data for Foghorn Therapeutics' Retained Earnings shows a maximum YoY tumbled of 62.18% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Foghorn Therapeutics' Retained Earnings stood at -$162.9 million in 2020, then plummeted by 62.18% to -$264.3 million in 2021, then slumped by 41.20% to -$373.1 million in 2022, then dropped by 26.38% to -$471.6 million in 2023, then fell by 18.37% to -$558.2 million in 2024.